Noninvasive prenatal testing creates an opportunity for antenatal treatment of Down syndrome

Prenatal Diagnosis

Volumn 33, Issue 6, 2013, Pages 614-618

  Guedj, Faycal ^a   Bianchi, Diana W ^a,b  

^a TUFTS MEDICAL CENTER   (United States)

^b TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

VASOACTIVE INTESTINAL POLYPEPTIDE;

BRAIN DEVELOPMENT; BRAIN DISEASE; CHROMOSOME 21; DOWN SYNDROME; GENE EXPRESSION; HISTOPATHOLOGY; HUMAN; NON INVASIVE PRENATAL TESTING; NONHUMAN; PHENOTYPE; PREGNANCY TERMINATION; PREGNANT WOMAN; PRENATAL CARE; PRENATAL DIAGNOSIS; PRENATAL SCREENING; PRIORITY JOURNAL; REVIEW; TERATOGENICITY; TRISOMY 21;

ADULT; ANIMALS; BRAIN; DISEASE MODELS, ANIMAL; DOWN SYNDROME; FEMALE; FETOSCOPY; HUMANS; MICE; PREGNANCY; PRENATAL DIAGNOSIS;

EID: 84878121111     PISSN: 01973851     EISSN: 10970223     Source Type: Journal    
DOI: 10.1002/pd.4134     Document Type: Review

References (28)

1. Ralston SJ, Wertz D, Chelmow D, et al. Pregnancy outcomes after prenatal diagnosis of aneuploidy. Obstet Gynecol 2001;97:729-33.
2. Cocchi G, Gualdi S, Bower C, et al. International trends of Down syndrome 1993-2004: births in relation to maternal age and terminations of pregnancies. A Clin Mol Teratol 2010;88:474-9.
3. Morris JK, Alberman E. Trends in Down's syndrome live births and antenatal diagnoses in England and Wales from 1989 to 2008: analysis of data from the National Down Syndrome Cytogenetic Register. BMJ 2009;339:b3794.
4. van Gameren-Oosterom HB, Buitendijk SE, Bilardo CM, et al. Unchanged prevalence of Down syndrome in the Netherlands: results from an 11-year nationwide birth cohort. Prenat Diagn 2012;32:1035-40.
5. Egan JF, Smith K, Timms D, et al. Demographic differences in Down syndrome livebirths in the US from 1989 to 2006. Prenat Diagn 2011;31:389-94.
6. Natoli JL, Ackerman DL, McDermott S, et al. Prenatal diagnosis of Down syndrome: a systematic review of termination rates (1995-2011). Prenat Diagn 2012;32:142-53.
7. Winter TC, Ostrovsky AA, Komarniski CA, Uhrich SB. Cerebellar and frontal lobe hypoplasia in fetuses with trisomy 21: usefulness as combined ultrasound markers. Radiology 2000;214:533-8.
8. Guihard-Costa AM, Khung S, Delbecque K, et al. Biometry of face and brain in fetuses with trisomy 21. Pediatr Res 2006;59:33-8.
9. Schmidt-Sidor B, Wisniewski KE, Shepard TH, et al. Brain growth in Down syndrome subjects 15 to 22 weeks of gestational age and birth to 60 months. Clin Neuropathol 1990;9:181-90
10. Guidi S, Bonasoni P, Ceccarelli C, et al. Neurogenesis impairment and increased cell death reduce total neuron number in the hippocampal region of fetuses with Down syndrome. Brain Pathol 2008;18:180-97.
11. Guidi S, Ciani E, Bonasoni P, et al. Widespread proliferation impairment and hypocellularity in the cerebellum of fetuses with Down syndrome. Brain Pathol 2011;21:361-73.
12. Weitzdoerfer R, Dierssen M, Fountoulakis M, et al. Fetal life in Down syndrome starts with normal neuronal density but impaired dendritic spines and synaptosomal structure. J Neural Transm Suppl 2001;61:59-70.
13. Petit TL, LeBoutillier JC, Alfano DP, et al. Synaptic development in the human fetus: a morphometric analysis of normal and Down's syndrome neocortex. Exp Neurol 1984;83:13-23.
14. Mao R, Wang X, Spitznagel EL Jr, et al. Primary and secondary transcriptional effects in the developing human Down syndrome brain and heart. Genome Biology 2005;6:R107.
15. Hui L, Slonim DK, Wick HC, et al. The amniotic fluid transcriptome: a source of novel information about human fetal development. Obstet Gynecol 2012;119(1):111-8.
16. Slonim DK, Koide K, Johnson KL, et al. Functional genomic analysis of amniotic fluid cell-free mRNA suggests that oxidative stress is significant in Down syndrome fetuses. Proc Natl Acad Sci USA 2009;106:9425-9.
17. Hui L, Slonim DK, Wick HC, et al. Novel neurodevelopmental information revealed in amniotic fluid supernatant transcripts from fetuses with trisomies 18 and 21. Hum Genet 2012;131:1751-9.
18. Haydar TF, Reeves RH. Trisomy 21 and early brain development. Trends Neurosci 2012;35:81-91.
19. Olson LE, Roper RJ, Baxter LL, et al. Down syndrome mouse models Ts65Dn, Ts1Cje, and Ms1Cje/Ts65Dn exhibit variable severity of cerebellar phenotypes. Dev Dyn 2004;230:581-9.
20. Baxter LL, Moran TH, Richtsmeier JT, et al. Discovery and genetic localization of Down syndrome cerebellar phenotypes using the Ts65Dn mouse. Hum Mol Genet 2000;9195-202.
21. Chakrabarti L, Galdzicki Z and Haydar TF. Defects in embryonic neurogenesis and initial synapse formation in the forebrain of the Ts65Dn mouse model of Down syndrome. J Neurosci 2007;27:11483-95.
22. Ishihara K, Amano K, Takaki E, et al. Enlarged brain ventricles and impaired neurogenesis in the Ts1Cje and Ts2Cje mouse models of Down syndrome. Cereb Cortex 2010;20:1131-43.
23. Lorenzi HA, Reeves RH. Hippocampal hypocellularity in the Ts65Dn mouse originates early in development. Brain Res 2006;1104:153-9.
24. Laffaire J, Rivals I, Dauphinot L, et al. Gene expression signature of cerebellar hypoplasia in a mouse model of Down syndrome during postnatal development. BMC Genomics 2009;10:138.
25. Nelson PG, Kuddo T, Song EY, et al. Selected neurotrophins, neuropeptides, and cytokines: developmental trajectory and concentrations in neonatal blood in children with autism or Down syndrome. Int J Dev Neurosci 2006; 24:73-80.
26. Incerti M, Horowitz K, Roberson R, et al. Prenatal treatment prevents learning deficit in a Down syndrome model. PLoS One 2012;7:e50724.
27. Vink J, Incerti M, Toso L, et al. Prenatal NAP+SAL prevents developmental delay in a mouse model of Down syndrome through effects on N-methyl-D-aspartic acid and gamma-aminobutyric acid receptors. Am J Obstet Gynecol 2009;200:524.e1-4.
28. Guedj F, Hines D, Foley JC, et al. Translating the transcriptome to develop antenatal treatments for fetuses with Down syndrome. Reprod Sci 2013;20(3) (Suppl):64A.